ORGANOGENESIS HOLDINGS INC (ORGO) Stock Fundamental Analysis

NASDAQ:ORGO • US68621F1021

3 USD
-0.21 (-6.54%)
At close: Mar 2, 2026
3.16 USD
+0.16 (+5.33%)
After Hours: 3/2/2026, 6:42:50 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to ORGO. ORGO was compared to 520 industry peers in the Biotechnology industry. While ORGO belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. ORGO has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • In the past year ORGO was profitable.
  • In the past year ORGO has reported a negative cash flow from operations.
  • Of the past 5 years ORGO 4 years were profitable.
  • Of the past 5 years ORGO 4 years had a positive operating cash flow.
ORGO Yearly Net Income VS EBIT VS OCF VS FCFORGO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M

1.2 Ratios

  • The Return On Assets of ORGO (2.65%) is better than 88.65% of its industry peers.
  • With an excellent Return On Equity value of 3.65%, ORGO belongs to the best of the industry, outperforming 89.81% of the companies in the same industry.
  • Looking at the Return On Invested Capital, with a value of 8.83%, ORGO belongs to the top of the industry, outperforming 93.46% of the companies in the same industry.
  • ORGO had an Average Return On Invested Capital over the past 3 years of 5.16%. This is significantly below the industry average of 18.99%.
  • The 3 year average ROIC (5.16%) for ORGO is below the current ROIC(8.83%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 2.65%
ROE 3.65%
ROIC 8.83%
ROA(3y)1.41%
ROA(5y)5.82%
ROE(3y)2.05%
ROE(5y)10.24%
ROIC(3y)5.16%
ROIC(5y)7.22%
ORGO Yearly ROA, ROE, ROICORGO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100

1.3 Margins

  • ORGO's Profit Margin of 2.81% is amongst the best of the industry. ORGO outperforms 88.46% of its industry peers.
  • In the last couple of years the Profit Margin of ORGO has declined.
  • ORGO has a better Operating Margin (9.90%) than 90.77% of its industry peers.
  • In the last couple of years the Operating Margin of ORGO has grown nicely.
  • With an excellent Gross Margin value of 75.62%, ORGO belongs to the best of the industry, outperforming 83.85% of the companies in the same industry.
  • ORGO's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 9.9%
PM (TTM) 2.81%
GM 75.62%
OM growth 3Y26.04%
OM growth 5Y4.64%
PM growth 3Y1.07%
PM growth 5Y-6.94%
GM growth 3Y-0.48%
GM growth 5Y0.38%
ORGO Yearly Profit, Operating, Gross MarginsORGO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • ORGO has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • The number of shares outstanding for ORGO has been increased compared to 1 year ago.
  • The number of shares outstanding for ORGO has been reduced compared to 5 years ago.
  • The debt/assets ratio for ORGO is higher compared to a year ago.
ORGO Yearly Shares OutstandingORGO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
ORGO Yearly Total Debt VS Total AssetsORGO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

2.2 Solvency

  • ORGO has an Altman-Z score of 3.25. This indicates that ORGO is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 3.25, ORGO is in the better half of the industry, outperforming 67.50% of the companies in the same industry.
  • ORGO has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
  • ORGO's Debt to Equity ratio of 0.03 is in line compared to the rest of the industry. ORGO outperforms 43.27% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z 3.25
ROIC/WACC1.04
WACC8.47%
ORGO Yearly LT Debt VS Equity VS FCFORGO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M 400M

2.3 Liquidity

  • ORGO has a Current Ratio of 3.62. This indicates that ORGO is financially healthy and has no problem in meeting its short term obligations.
  • ORGO has a Current ratio of 3.62. This is comparable to the rest of the industry: ORGO outperforms 43.27% of its industry peers.
  • A Quick Ratio of 3.32 indicates that ORGO has no problem at all paying its short term obligations.
  • ORGO has a Quick ratio of 3.32. This is comparable to the rest of the industry: ORGO outperforms 41.92% of its industry peers.
Industry RankSector Rank
Current Ratio 3.62
Quick Ratio 3.32
ORGO Yearly Current Assets VS Current LiabilitesORGO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • ORGO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 52.94%, which is quite impressive.
  • The Earnings Per Share has been growing by 16.72% on average over the past years. This is quite good.
  • Looking at the last year, ORGO shows a quite strong growth in Revenue. The Revenue has grown by 17.04% in the last year.
  • The Revenue has been growing by 10.77% on average over the past years. This is quite good.
EPS 1Y (TTM)52.94%
EPS 3Y25.99%
EPS 5Y16.72%
EPS Q2Q%416.67%
Revenue 1Y (TTM)17.04%
Revenue growth 3Y7.76%
Revenue growth 5Y10.77%
Sales Q2Q%78.13%

3.2 Future

  • Based on estimates for the next years, ORGO will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.84% on average per year.
  • Based on estimates for the next years, ORGO will show a quite strong growth in Revenue. The Revenue will grow by 8.18% on average per year.
EPS Next Y-43.12%
EPS Next 2Y18.84%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year6.33%
Revenue Next 2Y8.18%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ORGO Yearly Revenue VS EstimatesORGO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M
ORGO Yearly EPS VS EstimatesORGO Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.2 -0.2 0.4 -0.4 0.6

More info and screens

Find the best growth stocksShow best growing peers

5

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 11.54 indicates a reasonable valuation of ORGO.
  • Based on the Price/Earnings ratio, ORGO is valued cheaper than 96.73% of the companies in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 27.13, ORGO is valued rather cheaply.
  • A Price/Forward Earnings ratio of 20.28 indicates a rather expensive valuation of ORGO.
  • Based on the Price/Forward Earnings ratio, ORGO is valued cheaply inside the industry as 92.69% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 28.11, ORGO is valued a bit cheaper.
Industry RankSector Rank
PE 11.54
Fwd PE 20.28
ORGO Price Earnings VS Forward Price EarningsORGO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, ORGO is valued cheaper than 98.65% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 4.51
ORGO Per share dataORGO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

  • ORGO has a very decent profitability rating, which may justify a higher PE ratio.
  • ORGO's earnings are expected to grow with 18.84% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)0.69
EPS Next 2Y18.84%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • ORGO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ORGANOGENESIS HOLDINGS INC

NASDAQ:ORGO (3/2/2026, 6:42:50 PM)

After market: 3.16 +0.16 (+5.33%)

3

-0.21 (-6.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)05-06
Inst Owners54.62%
Inst Owner Change-0.51%
Ins Owners31.34%
Ins Owner Change1.22%
Market Cap380.73M
Revenue(TTM)564.17M
Net Income(TTM)15.85M
Analysts85
Price Target8.67 (189%)
Short Float %19.27%
Short Ratio12.19
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)106.05%
Min EPS beat(2)44.72%
Max EPS beat(2)167.38%
EPS beat(4)2
Avg EPS beat(4)16.53%
Min EPS beat(4)-73%
Max EPS beat(4)167.38%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)19.19%
Min Revenue beat(2)10.3%
Max Revenue beat(2)28.08%
Revenue beat(4)2
Avg Revenue beat(4)6.94%
Min Revenue beat(4)-6.36%
Max Revenue beat(4)28.08%
Revenue beat(8)6
Avg Revenue beat(8)7.04%
Revenue beat(12)7
Avg Revenue beat(12)4.32%
Revenue beat(16)7
Avg Revenue beat(16)2.3%
PT rev (1m)0%
PT rev (3m)6.25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)23.53%
EPS NY rev (1m)0%
EPS NY rev (3m)216.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3.66%
Revenue NY rev (1m)0%
Revenue NY rev (3m)5.49%
Valuation
Industry RankSector Rank
PE 11.54
Fwd PE 20.28
P/S 0.67
P/FCF N/A
P/OCF N/A
P/B 0.88
P/tB 0.96
EV/EBITDA 4.51
EPS(TTM)0.26
EY8.67%
EPS(NY)0.15
Fwd EY4.93%
FCF(TTM)-0.19
FCFYN/A
OCF(TTM)-0.08
OCFYN/A
SpS4.45
BVpS3.42
TBVpS3.12
PEG (NY)N/A
PEG (5Y)0.69
Graham Number4.47
Profitability
Industry RankSector Rank
ROA 2.65%
ROE 3.65%
ROCE 11.21%
ROIC 8.83%
ROICexc 10.88%
ROICexgc 12%
OM 9.9%
PM (TTM) 2.81%
GM 75.62%
FCFM N/A
ROA(3y)1.41%
ROA(5y)5.82%
ROE(3y)2.05%
ROE(5y)10.24%
ROIC(3y)5.16%
ROIC(5y)7.22%
ROICexc(3y)6.81%
ROICexc(5y)10.02%
ROICexgc(3y)7.75%
ROICexgc(5y)12.19%
ROCE(3y)6.54%
ROCE(5y)9.15%
ROICexgc growth 3Y14.91%
ROICexgc growth 5Y-14%
ROICexc growth 3Y18.93%
ROICexc growth 5Y-6.02%
OM growth 3Y26.04%
OM growth 5Y4.64%
PM growth 3Y1.07%
PM growth 5Y-6.94%
GM growth 3Y-0.48%
GM growth 5Y0.38%
F-Score2
Asset Turnover0.94
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA 0.17
Cap/Depr 76.1%
Cap/Sales 2.51%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.62
Quick Ratio 3.32
Altman-Z 3.25
F-Score2
WACC8.47%
ROIC/WACC1.04
Cap/Depr(3y)97.86%
Cap/Depr(5y)180.1%
Cap/Sales(3y)3.4%
Cap/Sales(5y)4.88%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52.94%
EPS 3Y25.99%
EPS 5Y16.72%
EPS Q2Q%416.67%
EPS Next Y-43.12%
EPS Next 2Y18.84%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)17.04%
Revenue growth 3Y7.76%
Revenue growth 5Y10.77%
Sales Q2Q%78.13%
Revenue Next Year6.33%
Revenue Next 2Y8.18%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y159.64%
EBIT growth 3Y35.82%
EBIT growth 5Y15.91%
EBIT Next Year246.7%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-685.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-172.56%
OCF growth 3YN/A
OCF growth 5YN/A

ORGANOGENESIS HOLDINGS INC / ORGO FAQ

Can you provide the ChartMill fundamental rating for ORGANOGENESIS HOLDINGS INC?

ChartMill assigns a fundamental rating of 5 / 10 to ORGO.


Can you provide the valuation status for ORGANOGENESIS HOLDINGS INC?

ChartMill assigns a valuation rating of 5 / 10 to ORGANOGENESIS HOLDINGS INC (ORGO). This can be considered as Fairly Valued.


What is the profitability of ORGO stock?

ORGANOGENESIS HOLDINGS INC (ORGO) has a profitability rating of 7 / 10.


What is the financial health of ORGANOGENESIS HOLDINGS INC (ORGO) stock?

The financial health rating of ORGANOGENESIS HOLDINGS INC (ORGO) is 5 / 10.